Also categorized in Clinical Research:
A Phase I Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors
x hide permanently

PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD2 antibody ch14.18/CHO.

ncbi.nlm.nih.gov

PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD2 antibody ch14.18/CHO.

Oncoimmunology. 2017;6(10):e1343775

Authors: Siebert N, Zumpe M, Jüttner M, Troschke-Meurer S, Lode HN

Abstract Immunotherapy with anti-GD2 antibody (Ab) ch14.18/CHO is effective for treatment of high-risk neuroblastoma (NB) patients and is mainly based on GD2-specific Ab-dependent cellular cytotoxicity (ADCC).

Mentions: Antibody Treatment Immunotherapy